FIELD: biotechnology.
SUBSTANCE: described is a vaccine for controlling HBS-associated parvovirus in pigs. Vaccine contains an immunogenically effective amount of a capsid protein (CP) encoded by a DNA fragment containing a gene coding CP. Nucleotide sequence of said gene has a level of identity of at least 80% relative to the nucleotide sequence of the CP gene, as shown in SEQ ID NO: 1, and a pharmaceutically acceptable carrier. Also described is a kit for diagnostic testing, comprising a set of primers for PCR, as shown in SEQ ID NO: 5 and 6, which specifically reacts with a portion of the capsid protein of HBS-associated porcine parvovirus, or a set of primers as shown in SEQ ID NO: 7 and 8, which specifically reacts with a portion of the NS1 gene of the HBS-associated porcine parvovirus.
EFFECT: invention extends the range of agents for controlling HBS-associated parvovirus in pigs.
2 cl, 3 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
| INFLUENZA VIRUS CAPABLE OF INFECTING CANINES AND ITS USE | 2020 |
|
RU2802222C2 |
| HERPES VACCINE | 2019 |
|
RU2731073C1 |
| NUCLEIC ACID CONSTRUCTIONS AND VECTORS FOR GENOTHERAPY FOR TREATING WILSON'S DISEASE AND OTHER CONDITIONS | 2015 |
|
RU2745567C2 |
| IMMUNOGENIC COMPOSITIONS OF GLYCOPROTEIN G OF HENDRA AND NIPAH VIRUSES | 2012 |
|
RU2787820C2 |
| BIOSENSOR SYSTEM FOR FAST DETECTION OF DETERMINED COMPONENTS | 2016 |
|
RU2717658C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| HIV-1 SUBTYPE A P17 PROTEIN ANTIBODIES | 2019 |
|
RU2727673C1 |
| IMMUNO-INDUCING AGENT | 2016 |
|
RU2744843C2 |
